Remepy is Pioneering Hybrid Drugs™. 
We believe that in the future, software applications will become an integral part of treatments offered by Pharma companies in the form of Hybrid Drugs™. These will include both a software component and a traditional drug component - influencing patients via Hybrid Mechanisms of Action™.

Remepy’s Digital Molecules™ are designed to be the software components within Hybrid Drugs™. They are based on digital interventions and treatment protocols that are tailored to each medical condition and its corresponding drug. 
The Digital Molecules™ enhance brain functions that balance the patient's neuro-endocrine and neuro-immunological systems and boost brain neuroplasticity, in order to optimize drug performance. 

Remepy partners with pharma companies to bring Hybrid Drugs™ to market that will combine  Remepy’s Digital Molecule™ and traditional drug components.

Pharmaceutical

Remepy

Or Shoval

Sheila Oren

Michal Tsur

Lior Benderski

Shai Elrich

Shahar Shelly

Nira Saporta

Jonathan Amit - Kanarek

Amir Amedi

The Leadership Team at Remepy oversees the strategic direction, financial health, product development, clinical operations, and scientific advancements of the company. They are responsible for ensuring the seamless integration of Digital Molecules™ with traditional drug components, fostering partnerships with pharma companies, and driving innovation in Hybrid Drugs™ to enhance patient outcomes.

Leadership Team

Medical and Clinical Team

Engineering Team

Leadership Team

About

Team members

Other teams at Remepy

Medical and Clinical Team

Engineering Team